MedTrace Logo

DP-R213 Phase 1 Pharmacokinetics Study

NCT03010267 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2017-06-05

No results posted yet for this study

Summary

A randomized, open-label, crossover, Phase I clinical trial to compare the pharmacokinetics of DP-R213 (Raloxifenel and Cholecaliferol fixed dose combinations) in comparison to each component administered alone in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

DP-R213

Investigational product is prescribed to all of randomized subjects

DRUG

Raloxifene

Investigational product is prescribed to all of randomized subjects

DRUG

Cholecaliferol

Investigational product is prescribed to all of randomized subjects

Sponsors & Collaborators

  • Alvogen Korea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-03
Primary Completion
2017-03-08
Completion
2017-03-29

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03010267 on ClinicalTrials.gov